Dr. Reddy's Laboratories Limited

NYSE:RDY Stock Report

Market Cap: US$11.4b

Dr. Reddy's Laboratories Past Earnings Performance

Past criteria checks 2/6

Dr. Reddy's Laboratories has been growing earnings at an average annual rate of 23.1%, while the Pharmaceuticals industry saw earnings growing at 8.6% annually. Revenues have been growing at an average rate of 13.1% per year. Dr. Reddy's Laboratories's return on equity is 14.9%, and it has net margins of 16.4%.

Key information

23.11%

Earnings growth rate

23.01%

EPS growth rate

Pharmaceuticals Industry Growth5.95%
Revenue growth rate13.08%
Return on equity14.94%
Net Margin16.36%
Last Earnings Update31 Dec 2025

Recent past performance updates

Recent updates

Dr. Reddy's: Needs To Invest $0.95 To Produce $1 Of New Revenues

Aug 04

Dr. Reddy's Lab: Near-Term Worries And Underappreciated Potential Could Lead To Huge Returns

Jan 30

Dr. Reddy's Laboratories: Economic Factors Square Off To Reiterate Buy

Aug 13

Dr. Reddy's Laboratories: Q2 Earnings Reveals Strong Growth And Promising Advancements

Nov 29

Dr. Reddy's: Continued Q2 Earnings Growth, Supports Long-Term Investment Outlook

Oct 27

Dr. Reddy's: Growth Supported By New Labels, Profitability

Aug 23

Dr. Reddy's Laboratories: Unpacking The Critical Factors, Reiterate Buy

Jun 07

Dr. Reddy's Laboratories: Positive Q3 Results, Growth Supportive Of Buy

Feb 16

Dr. Reddy's prepare to file for Rituxan biosimilar in US, EU as trials completed

Jan 20

Dr. Reddy's Needs Time For Generics Sales To Replace Sputnik Revenue

Nov 07

Dr. Reddy's GAAP EPS of $0.90, revenue of $660M misses by $12.78M

Jul 28

Dr. Reddy's launches generic drugs for allergies in US

Jul 22

Dr. Reddy's, EQRx team up to develop drugs for cancer, immune-inflammatory diseases

Jul 05

Revenue & Expenses Breakdown

How Dr. Reddy's Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NYSE:RDY Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 25345,83156,587102,03925,853
30 Sep 25342,14958,62299,23826,362
30 Jun 25334,26056,80295,80927,431
31 Mar 25325,53556,54492,85327,380
31 Dec 24311,30553,67690,01126,999
30 Sep 24299,86753,33286,12225,906
30 Jun 24288,50755,57981,91024,082
31 Mar 24279,16455,68476,92122,873
31 Dec 23271,30252,20674,71721,362
30 Sep 23266,85450,88872,47020,618
30 Jun 23261,10947,21670,23520,040
31 Mar 23245,87945,06768,02619,381
31 Dec 22237,27936,35065,70818,341
30 Sep 22222,77630,94463,13817,679
30 Jun 22217,35129,73662,52917,273
31 Mar 22214,39123,56862,08117,482
31 Dec 21207,30726,31760,71717,250
30 Sep 21203,40619,45059,69317,199
30 Jun 21194,74117,15356,84917,095
31 Mar 21189,72217,23854,65016,541
31 Dec 20186,75621,25652,45716,637
30 Sep 20181,29815,36150,74016,478
30 Jun 20180,34018,66350,85015,781
31 Mar 20174,60019,49850,12915,410
31 Dec 19170,44816,20050,24614,882
30 Sep 19165,11026,74949,48414,601
30 Jun 19155,07920,86248,63915,059
31 Mar 19153,85118,79548,68015,607
31 Dec 18149,03417,47348,40016,293
30 Sep 18148,59415,96548,54017,292
30 Jun 18145,90313,77647,20017,347
31 Mar 18141,8559,80646,85718,265
31 Dec 17141,8279,90945,37018,458
30 Sep 17140,58811,26644,66318,747
30 Jun 17140,90711,36745,40519,786
31 Mar 17139,87012,03946,30019,513
31 Dec 16141,2699,66046,96119,718
30 Sep 16144,12710,75147,65918,857
30 Jun 16148,41015,01946,94318,116
31 Mar 16153,86620,01345,64117,701
31 Dec 15155,85024,45644,15218,100
30 Sep 15154,60224,40943,26418,321
30 Jun 15150,59222,93242,87917,961
31 Mar 15147,36022,17942,07617,329

Quality Earnings: RDY has high quality earnings.

Growing Profit Margin: RDY's current net profit margins (16.4%) are lower than last year (17.2%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: RDY's earnings have grown significantly by 23.1% per year over the past 5 years.

Accelerating Growth: RDY's earnings growth over the past year (5.4%) is below its 5-year average (23.1% per year).

Earnings vs Industry: RDY earnings growth over the past year (5.4%) did not outperform the Pharmaceuticals industry 14.9%.

Return on Equity

High ROE: RDY's Return on Equity (14.9%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/03 22:31
End of Day Share Price 2026/02/03 00:00
Earnings2025/12/31
Annual Earnings2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Dr. Reddy's Laboratories Limited is covered by 79 analysts. 35 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Prashant NairAmbit Capital
Nitin BhasinAmbit Capital
Ashwin MehtaAmbit Capital